Gisela H. Degen - Concepedia

Author

Gisela H. Degen

Also Known As

Degen, G. H., Degen, Gisela, Degen, Gisela H., Detlef Wölfle, Eugenia Cordelli, G DEGEN, G Degen, G H Degen, G. Degen, G. H. Degen

311

Publications

7.6K

Citations

H-Index

144

Concepts

All Affiliations

TU Dortmund University Leibniz Research Centre for Working Environment and Human Factors German Sport University Cologne University of Würzburg Shahjalal University of Science and Technology

About

Gisela H. Degen is an author at TU Dortmund University specializing in medicine, toxicology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	89	4.3K
2	Health Sciences	16	16	950
3	Public Health	15	16	760
4	Natural Sciences	9	9	205
5	Engineering	6	6	177

Gisela H. Degen

125

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
The major metabolite of aflatoxin B1 in the rat is a glutathione conjugate Gisela H. Degen, Hans‐Günter Neumann Chemico-Biological Interactions Major MetaboliteBiochemistryAflatoxin B1MedicineMycotoxin Formation	1978	194
Antioxidant activities of major thyme ingredients and lack of (oxidative) DNA damage in V79 Chinese hamster lung fibroblast cells at low levels of carvacrol and thymol Ülkü Ündeğer, Arif Ahmet Başaran, Gisela H. Degen, Food and Chemical Toxicology Dna DamageAllergyRespiratory ToxicologyLipid PeroxidationImmunology	2009	173
A comparative study of the human urinary mycotoxin excretion patterns in Bangladesh, Germany, and Haiti using a rapid and sensitive LC-MS/MS approach Johannes Gerding, Nurshad Ali, Jeremy Schwartzbord, Mycotoxin Research UrologyMycotoxin FormationGlobal HealthBioanalysisFood Mycology	2015	149
Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement Roland Solecki, Andreas Kortenkamp, Åke Bergman, Archives of Toxicology	2016	146
SCCP (Scientific Committee on Consumer Products) / SCHER (Scientific Committee on Health& Environment Risks) / SCENIHR (Scientific Committee on Emerging and Newly- Identified Health Risks) opinion on: Risk assessment methodologies and approaches for genotoxic and carcinogenic substances Herman Autrup, James Bridges, Gisela H. Degen, Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)	2009	139
Differences in aflatoxin B<sub>1</sub>-susceptibility of rat and mouse are correlated with the capability <i>in vitro</i> to inactivate aflatoxin B<sub>1</sub>- epoxide Gisela H. Degen, Hans‐Günter Neumann Carcinogenesis InflammationMolecular PharmacologyJournal Article DifferencesAllergyImmunotoxicology	1981	138
Estrogenic isoflavones in rodent diets Gisela H. Degen, Petra Janning, Patrick Diel, Toxicology Letters Estrogenic IsoflavonesMedicineEndocrinologyPharmacologyOvarian Hormone	2002	123
Morphologic and neoplastic transformation of Syrian hamster embryo fibroblasts by diethylstilbestrol and its analogs. John A. McLachlan, Annette Wong, Gisela H. Degen, PubMed Transformation FrequencyPathologyCell CultureCell ProliferationStructural Analogs	1982	109
Simultaneous analysis of ochratoxin A and its major metabolite ochratoxin alpha in plasma and urine for an advanced biomonitoring of the mycotoxin Katherine Muñoz, Meinolf Blaszkewicz, Gisela H. Degen Journal of Chromatography B BiochemistryMedicineMycotoxin FormationBioanalysisSimultaneous Analysis	2009	108
Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells Ana L. Di Virgilio, Keiko Iwami, Wim Wätjen, Toxicology Letters MedicineCell DeathPhytopharmacologyToxicologyPhytochemical	2004	101

Page 1